Horizon Therapeutics (HZNP)

Horizon Therapeutics Stock Forecast & Price Target

See the Price Targets and Ratings of:

Analyst Rating Consensus

Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HZNP Stock Price Prediction

Average Price Target

▲(70.52% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Horizon Therapeutics in the last 3 months. The average price target is $112.00 with a high forecast of $144.00 and a low forecast of $71.00. The average price target represents a 70.52% change from the last price of $65.68.
Highest Price Target$144.00Average Price Target$112.00Lowest Price Target$71.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Upside / Downside
Upgrade Banner
Bank of America Securities
Horizon Therapeutics (HZNP) PT Lowered to $141 at BofA SecuritiesBofA Securities analyst Jason Gerberry lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $141.00 (from $142.00) while maintaining a Buy rating.
Mizuho Securities
Horizon Therapeutics (HZNP) PT Lowered to $150 at GuggenheimGuggenheim analyst Yatin Suneja lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $150.00 (from $159.00) while maintaining a Buy rating.
Wells Fargo
Wells Fargo Sticks to Its Buy Rating for Horizon Therapeutics (HZNP)
Piper Sandler
Horizon Therapeutics (HZNP) Expert Call Takeaways - Piper SandlerThe analyst stated "On the whole, the commentary surrounding Horizons daxdilimab and dazodalibep (i.e., key assets acquired via last years Viela Bio transaction) was encouraging in that there appears to be appropriate alignment between the underlying targets of each product candidate and the specific clinical settings on which HZNP is focusing each agent. Given what in our view is continued high visibility into aggressive growth out of Tepezza and its emergence as a multi-billion dollar franchise (and hence a longer-term EBITDA CAGR potentially in excess of 20%), we do not believe that HZNP shares are ascribing meaningful value to the pipeline in the context of an EV/2022E EBITDA of ~14x."
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
VTYXVentyx Biosciences
PRVAPrivia Health Group
RXDXPrometheus Biosciences
IMCRImmunocore Holdings
SKINBeauty Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

HZNP Stock Forecast FAQ

What is HZNP’s average 12-month price target, according to analysts?
Based on analyst ratings, Horizon Therapeutics’s 12-month average price target is $112.00.
    What is HZNP’s upside potential, based on the analysts’ average price target?
    Horizon Therapeutics has 70.52% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HZNP a Buy, Sell or Hold?
          Horizon Therapeutics has a conensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Horizon Therapeutics’s price target?
            The average price target for Horizon Therapeutics is $112.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $144.00 ,the lowest forecast is $71.00. The average price target represents 70.52% Increase from the current price of $65.68.
              What do analysts say about Horizon Therapeutics?
              Horizon Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis